Carolina P. Schröder

Author

University Medical Center Groningen ORCID

Also Known As

C P Schröder, C Schröder, C. P. Schröder, C. Pia Schröder, C. Schroder, C.P. Schroder, C.P. Schröder, C.P. Schröder, Carolien P. Schröder, Carolina P Schröder

124

Publications

3.5K

Citations

H-Index

Concepts

All Affiliations

University Medical Center Groningen University of Groningen Amsterdam UMC Location Vrije Universiteit Amsterdam Utrecht University University Medical Center Utrecht

About

Carolina P. Schröder is an author at University Medical Center Groningen specializing in oncology, radiation oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.4K
2	Health Sciences	5	5	945
3	Engineering	2	2	409
4	Cell Biology	2	2	142
5	Immunology	1	1	118

Carolina P. Schröder

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer Eli Dijkers, Thijs H. Oude Munnink, Jos G. W. Kosterink, Clinical Pharmacology & Therapeutics	2010	792
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer Frederike Bensch, Elly L. van der Veen, Marjolijn N. Lub–de Hooge, Nature Medicine Oncologic ImagingPd-l1 BlockadeMedicineImmune Checkpoint InhibitorTherapeutic Imaging	2018	702
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial Géraldine Gebhart, Laetitia E. Lamberts, Zéna Wimana, Annals of Oncology Breast OncologyOncologyEngineeringOncologic ImagingCancer Detection	2015	341
Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake Marlous Arjaans, Thijs H. Oude Munnink, Sjoukje F. Oosting, Cancer Research Bevacizumab-induced NormalizationAngiogenesisBlood Vessel NormalizationMedicineBevacizumab Treatment	2013	118
89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft Thijs H. Oude Munnink, Maarten A. de Korte, Wouter B. Nagengast, European Journal of Cancer MedicineHuman Tumour XenograftPathologyHsp90 Inhibitor Nvp-auy922Tumor Suppressor	2009	98
Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition Jorianne Boers, Clasina M. Venema, Erik F. J. de Vries, European Journal of Cancer Metastatic Breast CancerEngineeringBreast OncologyCyclin-dependent Kinase InhibitionOncologic Imaging	2019	68
Comparative biodistribution analysis across four different <sup>89</sup>Zr-monoclonal antibody tracers—The first step towards an imaging warehouse Frederike Bensch, Michaël M. Smeenk, Suzanne C. van Es, Theranostics	2018	64
Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies Clasina M. Venema, Lemonitsa H. Mammatas, Carolina P. Schröder, Journal of Nuclear Medicine	2017	61
Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy Tineke Vandenbroucke, Magali Verheecke, Mathilde van Gerwen, European Journal of Cancer	2020	59
PET with the<sup>89</sup>Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models Thijs H. Oude Munnink, Marlous Arjaans, Hetty Timmer‐Bosscha, Journal of Nuclear Medicine	2011	54

Page 1